Synapse - Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)

Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL) Meeting Abstract

Authors:	Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; Ahsanuddin, S.; Callan, D.; Freidin, B.; Porzio, R.; Dang, T. O.; Ni, A.; Rademaker, J.; Schoder, H.; Dogan, A.; Younes, A.
Abstract Title:	Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
Meeting Title:	53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	35
Issue:	15 Suppl.
Meeting Dates:	2017 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2017-05-20
Start Page:	403s
Language:	English
ACCESSION:	WOS:000411931709031
DOI:	10.1200/JCO.2017.35.15_suppl.7544
PROVIDER:	wos
Notes:	Meeting Abstract: 7544 -- Source: Wos